Q-omics provides the consensus-scored ARHGAP28 profile across patient tissues and cancer cell-line models. ARHGAP28 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ARHGAP28 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, ARHGAP28 RNA expression shows 17,767 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, COAD, and TGCT as cancer lineages where ARHGAP28 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARHGAP28 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARHGAP28 survival associations across molecular data types. ARHGAP28 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (10) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARHGAP28 RNA expression–survival associations across cancer types. High ARHGAP28 expression shows unfavorable associations in STAD, BLCA and UCEC, but favorable associations in KIRC, UCS and DLBC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ARHGAP28 RNA expression.
This table summarizes ARHGAP28 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ARHGAP28. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARHGAP28 shows lower tumor expression in COAD, THCA, KIRP, UCEC and LUAD and higher tumor expression in HNSC. The COAD box plot shows higher ARHGAP28 RNA expression in normal versus tumor tissue (log2 FC = −0.560, t-test p < 0.001).
This table shows molecular features associated with ARHGAP28 in patient tissues and cancer cell lines. In patient samples, ARHGAP28 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ARHGAP28 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
